🇺🇸 Nicotine Transdermal Patch in United States
151 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 151
Most-reported reactions
- Drug Ineffective — 80 reports (52.98%)
- Malaise — 13 reports (8.61%)
- Nausea — 9 reports (5.96%)
- Nicotine Dependence — 9 reports (5.96%)
- Headache — 7 reports (4.64%)
- Insomnia — 7 reports (4.64%)
- Off Label Use — 7 reports (4.64%)
- Product Quality Issue — 7 reports (4.64%)
- Anxiety — 6 reports (3.97%)
- Application Site Erythema — 6 reports (3.97%)
Other Addiction Medicine / Smoking Cessation approved in United States
Frequently asked questions
Is Nicotine Transdermal Patch approved in United States?
Nicotine Transdermal Patch does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Nicotine Transdermal Patch in United States?
University of Southern California is the originator. The local marketing authorisation holder may differ — check the official source linked above.